Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Peter Rose, MD

216.444.6601

Peter Rose, MD

Appointed: 2004

Peter Rose, MD
Department: Obstetrics and Gynecology
Section Head, Gynecologic Oncology
Location: Cleveland Clinic Main Campus
Mail Code A81
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6601
WorkFax:216.444.8551
Peter Rose, MD
Department: Obstetrics and Gynecology
Section Head, Gynecologic Oncology
Location: Hillcrest Hospital
Mail Code Gyn Onc
6770 Mayfield Road
Mayfield Heights, OH 44124
WorkAppointment:440.312.5560
WorkFax:440.312.5562
Peter Rose, MD
Department: Obstetrics and Gynecology
Section Head, Gynecologic Oncology
Location: Moll Cancer Center at Fairview Hospital
18200 Lorain Road
Cleveland, OH 44111
WorkAppointment:216.476.7540
WorkFax:216.476.7420
Surgeon:
Yes
Treats:
Adults Only

Biographical Sketch

Peter G. Rose, MD, is Section Head and Fellowship Director of Gynecologic Oncology in the Department of Obstetrics and Gynecology at Cleveland Clinic. 

Dr. Rose attended the St. Louis School of Medicine in St. Louis, Mo., after completing his BA in biochemistry and biophysics from the University of Connecticut in Storrs, Conn.

Professional Highlights

  • Principal Investigator: Gynecologic Oncology Group, 1990-1992, 1995-Current
  • Study Chairman: Gynecologic Oncology Group, various trials
  • Study Chairman: SmithKline Beecham Pharmaceuticals. A Phase I study of oral topotecan and liposomal doxorubicin (Doxil) as second-line therapy in ovarian, peritoneal and tubal carcinoma. A Phase I/II study of carboplatin and topotecan as second-line therapy in platinum-sensitive ovarian or peritoneal carcinoma.
  • Study Chairman: Bristol-Myers Squibb Pharmaceuticals. A Phase II study of weekly paclitaxel and carboplatin as second-line therapy in platinum-sensitive ovarian or peritoneal carcinoma.
  • Study Chairman: Eli Lilly & Company. A phase II randomized study of gemcitabine and carboplatin utilizing two different dose schedules in patients with recurrent ovarian or peritoneal carcinoma.

Education & Fellowships

Fellowship - Roswell Park Cancer Institute
Gynecologic Oncology
Buffalo, NY USA
1988
Residency - The Ohio State University Hospitals
Obstetrics and Gynecology
Columbus, OH USA
1986
Residency - Vanderbilt University
Surgery
Nashville, TN USA
1983
Medical School - Boston University School of Medicine
Boston, MA USA
1981
Medical School - Saint Louis University School of Medicine
St. Louis, MO USA
1979
Undergraduate - University of Connecticut
Biochemistry and Biophysics
Storrs, CT USA
1977

Certifications

  • Obstetrics & Gynecology
  • Obstetrics & Gynecology- Gynecologic Oncology

Specialty Interests

Cervical Cancer, Endometrial Cancer, gynecologic cancer surgery, gynecologic oncology, Laparoscopic Surgery, molecular basis of gynecologic cancers, Ovarian Cancer, ovarian cancer screening and treatment, vulvar cancer

Awards & Honors

  • Faculty Teaching Award, Department of Obstetrics and Gynecology, University of Massachusetts, 1991
  • Faculty Teaching Award, Department of Obstetrics and Gynecology, Mt. Sinai Hospital, Cleveland, Ohio, 1994
  • Association of Professors of Obstetrics and Gynecology (APGO), Medical Student Teaching Award, Department of Obstetrics and Gynecology, University Hospitals of Cleveland, 1998
  • Best Doctors, Cleveland magazine, 1998, 2002, 2004, 2006-2008

Additional Training

  • Laser Certification, Grant Hospital, Columbus, Ohio, 1984 
  • Laser Certification, Roswell Park Memorial Institute, Buffalo, N.Y., 1988 

Memberships

  • Gynecologic Oncology Group Principal Investigator (PI): 2/1990-11/1992, 2/1995-7/2002, 1/2004-Current; Affiliate PI: 11/1992-2/1995, 7/2002-1/2004; Member, Developmental Therapeutics Committee: 1/1996-Current (Section Head, Cervical Cancer 1/2003); Member, Phase I Committee: 1/1997-Current; Member, Ovarian Committee: 1/1998-Current
  • Fellow, American College of Surgeons, 1992-1998
  • New England Cancer Society, 1991-1992
  • New England Association of Gynecologic Oncologists; Candidate Member 1989, Member 1992-Current
  • Society of Gynecologic Oncologists; Candidate Member 1989, Member 1992; Member Education Committee, 1994-1997; Editor of SGO Issues, 1995-1998; Member of the Communications Committee, 1996-1997; Member of the Coding Committee, 1999-Current; Member of the Program Committee, 2001

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/14/2014, Dr. Rose has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English